Operator of an oncology company intended to accelerate the impact of precision medicine for patients with cancer.
Operator of an oncology company intended to accelerate the impact of precision medicine for patients with cancer.
Decision/Risk Analysis📍 Ann Arbor, MIFounded 2015
Current Valuation
$590M
as of 2021-Q3
PRIVATE
QL Price
$590M
0% vs last round
QuantLogix's current estimate for Strata Oncology, published 2026-09-27 — in line with the last disclosed round of $590M (2021-Q3).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$590M
2021-Q3
weight 0.03
How this price has held up
No round has priced for Strata Oncology since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Strata Oncology, 2026-09-27 (e2415c401511281d).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Strata Oncology going public?
No. Strata Oncology is private and has not filed to go public. There is no S-1 on file.
What is Strata Oncology's valuation in 2026?
Strata Oncology is valued at $590M as of 2021-Q3, set by its Series C ($90M, Jul 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Strata Oncology filed an S-1?
No public S-1 is on file for Strata Oncology.
How much has Strata Oncology raised?
Strata Oncology has raised $133M in total, most recently a Series C of $90M in Jul 2021.
Is Strata Oncology publicly traded — can you buy Strata Oncology stock?
No. Strata Oncology is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Strata Oncology on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2015
HQ
Ann Arbor, MI
Employees
82
Total Raised
$133M
Last Round
Series C — $90M (Jul 2021)
IPO Status
private
Fundraising Status
Series C · $90M · 5y 2mo ago
privateTotal raised $133M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$90M
Jul 2021
—
$590M
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
4
0 active · 0 recruiting
Lead phase
Phase 2
most advanced registered study
Focus areas
Cancer
Advanced Solid Tumor · Adult Solid Tumor
Latest trial start
2023-02-06
Name-verified against lead sponsor "Strata Oncology" on ClinicalTrials.gov as of 2026-09-19. Verify on ClinicalTrials.gov ↗
Talent Signal
No public careers page or job board could be found for Strata Oncology as of 2026-09-17. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
Health CareBiotechnologyMedical DeviceGeneticsHealth Diagnostics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q3. Refreshed quarterly.